LQDA Insider Trading

Insider Ownership Percentage: 30.10%
Insider Buying (Last 12 Months): $1,426,500.00
Insider Selling (Last 12 Months): $1,811,792.50

Liquidia Insider Trading History Chart

This chart shows the insider buying and selling history at Liquidia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$410ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M-$5M$0$5M$10MTotal Insider BuyingTotal Insider Selling

Liquidia Share Price & Price History

Current Price: $13.72
Price Change: Price Increase of +0.04 (0.29%)
As of 04/17/2025 05:00 PM ET

This chart shows the closing price history over time for LQDA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$13.72Closing price on 04/17/25:

SEC Filings (Institutional Ownership Changes) for Liquidia (NASDAQ:LQDA)

64.54% of Liquidia stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at LQDA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$1.64Mbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100M$0$100MTotal InflowsTotal Outflows
Liquidia logo
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Read More on Liquidia

Today's Range

Now: $13.72
Low: $13.49
High: $14.06

50 Day Range

MA: $14.70
Low: $11.99
High: $16.52

52 Week Range

Now: $13.72
Low: $8.26
High: $16.81

Volume

597,870 shs

Average Volume

968,024 shs

Market Capitalization

$1.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23

Who are the company insiders with the largest holdings of Liquidia?

Liquidia's top insider shareholders include:
  1. Caligan Partners Lp (Director)
  2. Roger Jeffs (CEO)
  3. Russell Schundler (General Counsel)
  4. Michael Kaseta (CFO)
  5. Rajeev Saggar (Insider)
  6. Robert A Lippe (Insider)
  7. Jason Adair (Insider)
  8. Scott Moomaw (Insider)
Learn More about top insider investors at Liquidia.

Who are the major institutional investors of Liquidia?

Liquidia's top institutional shareholders include:
  1. Rhumbline Advisers — 0.10%
  2. SG Americas Securities LLC — 0.07%
  3. GAMMA Investing LLC — 0.05%
  4. Whitcomb & Hess Inc. — 0.02%
  5. GAMMA Investing LLC — 0.00%
Learn More about top institutional investors of Liquidia stock.

Which major investors are buying Liquidia stock?

Within the previous quarter, LQDA stock was purchased by institutional investors including:
  1. SG Americas Securities LLC
  2. GAMMA Investing LLC
  3. Whitcomb & Hess Inc.
  4. Rhumbline Advisers
  5. GAMMA Investing LLC
Within the last year, these company insiders have bought Liquidia stock:
  1. Caligan Partners Lp (Director)
  2. Roger Jeffs (CEO)
Learn More investors buying Liquidia stock.